Sasha Jovanovic
4 min read
Novo Nordisk has had a rough three years in the market, even as interest in its GLP-1 obesity and diabetes treatments has grown. This puts an unusual spotlight on what investors are actually paying for its earnings today. With the share price at DKK 272.70 after a year to date decline, the key issue is whether the current multiple lines up with the profit engine behind drugs like Wegovy.
-
Over the past 3 years, Novo Nordisk shares have fallen 55.9%, which means anyone buying or holding today is effectively rethinking what the business is worth on its earnings rather than momentum.
-
Recent updates on Wegovy, GLP-1 momentum and an expanded obesity pipeline point to earnings that can be more tied to obesity care demand and regulatory scrutiny, which may influence how much of those profits investors are comfortable capitalizing into the share price.
-
The analysts covering Novo Nordisk have run their own numbers. See what analysts think Novo Nordisk’s shares could be worth.
For investors, the debate is whether Novo Nordisk’s current price around DKK 272.70 is appropriately anchored to the earnings power of its GLP-1 portfolio or asking too much of that profit stream.
If you are weighing Novo Nordisk against other ways to play this theme, it can help to compare how the market is pricing similar stories using 196 high quality undervalued stocks.
Does Novo Nordisk Look Undervalued on Earnings?
The P/E ratio suits Novo Nordisk because earnings are a key focus for a mature, profitable drug maker. At the current price, the stock trades on a P/E of 10.6x, which is far below the Pharmaceuticals industry average of 20.9x and also well under the peer group on 35.7x. For a business tied closely to GLP-1 treatments, that is a relatively low headline earnings multiple.
The Fair Ratio model, which adjusts for margins, size, sector and risk, points to a higher P/E than where Novo Nordisk is trading, so the market price screens as undervalued on this framework. Because the recent upgrades to guidance on GLP-1 driven sales have not pulled the P/E closer to peer or modelled levels, the current tag still reflects a meaningful discount to what similar earnings streams are being priced at elsewhere. Explore the numbers behind Novo Nordisk’s P/E valuation.
The Novo Nordisk Narrative: What Would Justify Today’s Price?
Simply Wall St Narratives for Novo Nordisk pick up exactly where this valuation puzzle leaves off. They spell out which future paths for growth, profitability and earnings would need to play out for the stock to be worth materially more or materially less than today’s price on the Community page. Each scenario links its number to a clear view on how Novo Nordisk’s growth, margin profile and risk picture could evolve, giving you something concrete to revisit as fresh information comes through.
